| Dr Andrew Nicholson, MD | |
|
7300 Van Dusen Rd, Laurel, MD 20707-9463 | |
| (301) 725-4300 | |
| Not Available |
| Full Name | Dr Andrew Nicholson |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Location | 7300 Van Dusen Rd, Laurel, Maryland |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1356406417 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | D0045928 (Maryland) | Primary |
| Entity Name | Emergency Medicine Associates Pa Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1134117393 PECOS PAC ID: 8022914522 Enrollment ID: O20070919000389 |
News Archive
I will talk about the simple but fundamental idea that allowed breaking the diffraction barrier in fluorescence microscopy as well as about MINFLUX nanoscopy, the latest development in the field that for the first time provides true molecular resolution with visible light and standard objective lenses.
At a busy shopping mall, shoppers walk by store windows to find attractive items to purchase. Through the windows, shoppers can see the products displayed, but may have a hard time imagining doing something beyond just looking, such as touching the displayed items or communicating with sales assistants inside the store.
Researchers from GE Global Research announced today that they have been awarded a four-year, $4 million grant from the National Institutes of Health, to optimize a new nerve labeling agent and imaging system. In the future, this agent could help surgeons see delicate nerve endings that are prone to damage during certain procedures, such as prostate surgery.
A new programme to strengthen the UK's position as a leader in the methods that underpin health research has been announced by the Medical Research Council and the National Institute for Health Research.
IRIS International, Inc., a leading manufacturer of automated in-vitro diagnostics systems and consumables for use in hospitals and commercial laboratories worldwide, announced today that its IRIS Molecular Diagnostics (IMD) subsidiary has submitted a 510(k) pre-market notification application to the U.S. Food and Drug Administration (FDA) requesting regulatory clearance for NADiA®ProsVue™, a prostate cancer prognostic test. The test is designed to help physicians identify patients at low risk of cancer recurrence post radical prostatectomy.
› Verified 6 days ago
| Entity Name | Metropolitan Patient Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1154749158 PECOS PAC ID: 5597981001 Enrollment ID: O20140718000697 |
News Archive
I will talk about the simple but fundamental idea that allowed breaking the diffraction barrier in fluorescence microscopy as well as about MINFLUX nanoscopy, the latest development in the field that for the first time provides true molecular resolution with visible light and standard objective lenses.
At a busy shopping mall, shoppers walk by store windows to find attractive items to purchase. Through the windows, shoppers can see the products displayed, but may have a hard time imagining doing something beyond just looking, such as touching the displayed items or communicating with sales assistants inside the store.
Researchers from GE Global Research announced today that they have been awarded a four-year, $4 million grant from the National Institutes of Health, to optimize a new nerve labeling agent and imaging system. In the future, this agent could help surgeons see delicate nerve endings that are prone to damage during certain procedures, such as prostate surgery.
A new programme to strengthen the UK's position as a leader in the methods that underpin health research has been announced by the Medical Research Council and the National Institute for Health Research.
IRIS International, Inc., a leading manufacturer of automated in-vitro diagnostics systems and consumables for use in hospitals and commercial laboratories worldwide, announced today that its IRIS Molecular Diagnostics (IMD) subsidiary has submitted a 510(k) pre-market notification application to the U.S. Food and Drug Administration (FDA) requesting regulatory clearance for NADiA®ProsVue™, a prostate cancer prognostic test. The test is designed to help physicians identify patients at low risk of cancer recurrence post radical prostatectomy.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Andrew Nicholson, MD Po Box 227, Harwood, MD 20776-0227 Ph: () - | Dr Andrew Nicholson, MD 7300 Van Dusen Rd, Laurel, MD 20707-9463 Ph: (301) 725-4300 |
News Archive
I will talk about the simple but fundamental idea that allowed breaking the diffraction barrier in fluorescence microscopy as well as about MINFLUX nanoscopy, the latest development in the field that for the first time provides true molecular resolution with visible light and standard objective lenses.
At a busy shopping mall, shoppers walk by store windows to find attractive items to purchase. Through the windows, shoppers can see the products displayed, but may have a hard time imagining doing something beyond just looking, such as touching the displayed items or communicating with sales assistants inside the store.
Researchers from GE Global Research announced today that they have been awarded a four-year, $4 million grant from the National Institutes of Health, to optimize a new nerve labeling agent and imaging system. In the future, this agent could help surgeons see delicate nerve endings that are prone to damage during certain procedures, such as prostate surgery.
A new programme to strengthen the UK's position as a leader in the methods that underpin health research has been announced by the Medical Research Council and the National Institute for Health Research.
IRIS International, Inc., a leading manufacturer of automated in-vitro diagnostics systems and consumables for use in hospitals and commercial laboratories worldwide, announced today that its IRIS Molecular Diagnostics (IMD) subsidiary has submitted a 510(k) pre-market notification application to the U.S. Food and Drug Administration (FDA) requesting regulatory clearance for NADiA®ProsVue™, a prostate cancer prognostic test. The test is designed to help physicians identify patients at low risk of cancer recurrence post radical prostatectomy.
› Verified 6 days ago
Dr. Barry P Shapiro, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 7300 Van Dusen Rd, Laurel, MD 20707 Phone: 301-497-7954 | |
Dr. Jeffrey J Hong, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 575 Main Street, Suite 351, Laurel, MD 20707 Phone: 301-498-5990 | |
Peter Hammond, M.D. Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 7300 Van Dusen Rd, Laurel, MD 20707 Phone: 301-497-7954 | |
Puneet Chopra, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 13900 Baltimore Ave, Laurel, MD 20707 Phone: 301-725-5652 | |
Dr. David M Weber, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 3357b Corridor Marketplace, Laurel, MD 20724 Phone: 301-497-1820 | |
Dr. Carol Ann Nieroda, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 7300 Van Dusen Rd, Emergency Room, Laurel, MD 20707 Phone: 301-497-7954 |